Wednesday, 24 May 2017

Market Research Outlook on Obesity - Pipeline Review, H1 2017

Obesity - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.
Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.
Complete report available @ Obesity - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 16, 22, 129, 30 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 50 and 14 molecules, respectively.
Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Abeome Corp Adamas Pharmaceuticals Inc Advinus Therapeutics Ltd Aegis Therapeutics LLC Akron Molecules AG Alize Pharma SAS Amabiotics SAS Amgen Inc Aoxing Pharmaceutical Company Inc Arrowhead Pharmaceuticals Inc AstraZeneca Plc Asubio Pharma Co Ltd Athersys Inc Biophytis SAS BioRestorative Therapies Inc Biozeus Boehringer Ingelheim GmbH Braasch Biotech LLC C3J Therapeutics Inc Camurus AB Carmot Therapeutics Inc CohBar Inc CoMentis Inc Connexios Life Sciences Pvt Ltd ConSynance Therapeutics Inc Corium International Inc Daiichi Sankyo Company Ltd DiscoveryBiomed Inc Eisai Co Ltd Eli Lilly and Company Esperion Therapeutics Inc Eternygen GmbH Evotec AG F. Hoffmann-La Roche Ltd FibroGen Inc Genmedica Therapeutics SL Gila Therapeutics Inc Gilead Sciences Inc GlaxoSmithKline Plc Glucox Biotech AB GTx Inc HanAll Biopharma Co Ltd Hanmi Pharmaceuticals Co Ltd Hyundai Pharmaceutical Co Ltd Immungenetics AG Intarcia Therapeutics Inc Ionis Pharmaceuticals Inc Ixchel Pharma LLC Jenrin Discovery Inc Johnson & Johnson Laboratorios Silanes SA de CV Lead Discovery Center GmbH Leading BioSciences Inc Lotus Pharmaceutical Co Ltd M Pharmaceutical Inc Magnus Life Ltd MedImmune LLC Merck & Co Inc Mitochon Pharmaceuticals Inc Mitsubishi Tanabe Pharma Corp NeuroNano Pharma Inc NGM Biopharmaceuticals Inc NIBEC Nordic Bioscience A/S Novartis AG Novo Nordisk A/S ObeTherapy Biotechnology Omeros Corp OPKO Biologics Ltd OPKO Health Inc Pfizer Inc PharmaIN Corp Poxel SA Progenra Inc Prometheon Pharma LLC ReCyte Therapeutics Inc Renova Therapeutics Inc Reviva Pharmaceuticals Inc Saniona AB Sanofi Seoul Pharma Co Ltd Shionogi & Co Ltd Sinil Pharmaceutical Co Ltd Sorrento Therapeutics Inc Sumitomo Dainippon Pharma Co Ltd Takeda Pharmaceutical Company Ltd Toray Industries Inc Umecrine AB Vicore Pharma AB Viking Therapeutics Inc WhanIn Pharmaceutical Co Ltd Xenetic Biosciences Inc XL-protein GmbH Yuyu Pharma Inc Zafgen Inc Zealand Pharma AS
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home